65 results on '"Mortensen, J. H."'
Search Results
2. P384 Serum biomarkers of proteolytic type III and type IV collagen remodeling differentiate patients with Inflammatory Bowel Disease according to infliximab treatment response or non-response
3. P653 Impact of ozanimod on type III collagen turnover biomarkers and the association with ozanimod efficacy in patients with moderately to severely active ulcerative colitis: Results from the phase 3 True North study
4. P336 Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights
5. P136 Blood-based biomarkers of type III collagen remodeling as surrogate markers of endoscopic disease activity in patients with Ulcerative Colitis
6. P242 Immune-cell specific biomarker of early intestinal inflammation: Neutrophil elastase degraded fragment of type III collagen is elevated in patients with Inflammatory Bowel Disease
7. P308 CPa9-HNE: A NEUTROPHIL-DERIVED FRAGMENT OF CALPROTECTIN MEASURED IN SERUM CAN MONITOR ENDOSCOPIC AND CLINICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS
8. P197 A biomarker of early mucosal destruction: Neutrophil-mediated type IV collagen degradation is elevated in patients with Crohn’s Disease and Ulcerative Colitis
9. The good and the bad collagens of fibrosis – Their role in signaling and organ function
10. Femoral & Experimental
11. P611 Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease
12. P127 Type I collagen degradation fragments (C1M) and human neutrophil elastase-derived fragments of calprotectin (CPa9-HNE) reflect biochemical and endoscopic disease activity in patients with Inflammatory Bowel Disease
13. P460 Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn’s disease undergoing infliximab induction therapy
14. P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease
15. P123 Type I collagen degradation fragments and type IV collagen formation/degradation ratio are serological biomarkers for stricturing (Montreal B2) Crohn’s disease
16. P278 Type IV collagen formation/degradation ratio predicts response to infliximab induction therapy in patients with Ulcerative Colitis
17. Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease
18. A serological biomarker of type VIII collagen that contains the anti-angiogenic signalling molecule, vastatin, is associated with the extension of disease in ulcerative colitis
19. P087 Biomarkers of elastin degradation differentiate between clinically inactive and active disease in ulcerative colitis patients
20. P101 Biomarkers of elastin degradation are associated with clinical and biochemically active disease in Crohn’s disease
21. P047 Differences in extra cellular matrix remodelling in highly active Crohn’s disease and ulcerative colitis
22. Extracellular matrix fragments of the basement membrane and the interstitial matrix are markers of disease activity and disease progression
23. Basement membrane remodelling as a biomarker for monitoring disease activity in Crohn's disease patients: the role of laminin
24. Serum biomarkers reflecting tissue-remodelling correlates with the simple endoscopic score for Crohn's disease
25. Serological assessment of type XVI collagen reflects intestinal strictures in Crohn's disease patients
26. Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease
27. Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients
28. P282 Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn’s disease
29. P217 Serological biomarkers of type VI collagen remodelling reflect endoscopically and clinically active Crohn’s disease
30. P137 Serum biomarkers of degradation and formation of type III, IV and V collagen are associated with disease activity in patients with Crohn’s disease
31. P103 Degradation and formation of type III, IV and V collagen are associated with disease activity, disease severity and disease extension in patients with ulcerative colitis
32. P301 A serological biomarker of type VIII collagen that contains the anti-angiogenic signalling molecule, vastatin, is associated with the extension of disease in ulcerative colitis
33. Type V Collagen is Persistently Altered After Inguinal Hernia Repair
34. Type V Collagen is Persistently Altered After Inguinal Hernia Repair
35. MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn's disease
36. P265 Platelet activation by activated von Willebrand factor is a marker of intestinal wound healing in patients with Crohn’s disease
37. P125 Basement membrane remodelling as a biomarker for monitoring disease activity in Crohn’s disease patients: the role of laminin
38. P092 Serological assessment of wound healing in Crohn’s disease
39. P196 Serum biomarkers reflecting tissue-remodelling correlates with the simple endoscopic score for Crohn’s disease
40. P303 Serological assessment of type XVI collagen reflects intestinal strictures in Crohn’s disease patients
41. P015 Extracellular matrix fragments of the basement membrane and the interstitial matrix are markers of disease activity and disease progression
42. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease
43. Matrix Metalloproteinase Degraded Biglycan (BGM) and Citrullinated and MMP-degraded Vimentin (VICM) differentiates Crohn’s disease from ulcerative colitis
44. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.
45. Optimierung der Kesselregelung zur Verbesserung der Lastfolge von Kraftwerksblöcken
46. Optimization of Boiler Control to Improve the Load-following Capability of Power-plant Units
47. Development of an Optimizing Control Concept for Fossil-Fired Boilers using a Simulation Model
48. Kontrolstrategi til frigørelse af kraftværkers reguleringsevne
49. Optimization of Boiler Control for Improvement of Load Following Capabilities of Existing Power Plants
50. Ileocolonic Involvement and Diagnosis is Related to Fragments of the Extracellular Matrix Measured in Serum of Patients with Crohn's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.